From the analyst's couch: Wet age-related macular degeneration

Nature Reviews Drug Discovery

Volumn 4, Issue 9, 2005, Pages 711-712

  Melnikova, Irena ^a  

^a MEDACorp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS ACTING ON THE EYE; ALN VEG01; ANECORTAVE; BENZOPORPHYRIN DERIVATIVE; BEVACIZUMAB; CAND 5; EVIZON; PEGAPTANIB; PLACEBO; RANIBIZUMAB; RTP 801I; SIRNA 027; SQUALAMINE; UNCLASSIFIED DRUG; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ARTICLE; BLINDNESS; CLINICAL TRIAL; DRUG APPROVAL; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; HUMAN; PATIENT SELECTION; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RNA INTERFERENCE; VISUAL ACUITY; AGE; AGED; CLASSIFICATION; ECONOMICS; FORECASTING; MARKETING; MIDDLE AGED; PHOTOTHERAPY; RETINA MACULA DEGENERATION;

AGE FACTORS; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; FORECASTING; HUMANS; MACULAR DEGENERATION; MARKETING; MIDDLE AGED; PHOTOTHERAPY;

EID: 26044443312     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1827     Document Type: Article

References (2)

1. Schachat, A. P. New treatments for age-related macular degeneration. Ophthalmology 112, 531-532 (2005).
2. Karagiannis, T. C. & El-Osta, A. RNA interference and potential therapeutic applications of short interfering RNAs. Cancer Gene Ther. 13 May 2005 [Epub ahead of print].